期刊文献+

CIP2A在膀胱癌患者肿瘤组织及血清中的表达及其临床意义 被引量:3

Clinical significance of CIP2A expression in bladder cancer
原文传递
导出
摘要 目的 探讨蛋白磷酸酶2A的癌性抑制因子(CIP2A)在膀胱癌患者肿瘤组织和血清中的表达及其在膀胱癌发生发展中的作用.方法 对2010年5月至2012年12月山东大学第二医院泌尿外科收治的膀胱癌患者,采用反转录PCR (RT-PCR)检测38例患者的肿瘤组织和12例患者癌旁组织CIP2A mRNA的表达;免疫组化染色法检测99例患者肿瘤组织和12例患者癌旁组织中CIP2A蛋白表达;以ELISA法检测38例膀胱癌患者及40名健康对照者外周血中CIP2A蛋白的含量.结果 RT-PCR显示38例膀胱癌患者中29例(76.32%)检测到CIP2A mRNA的表达,癌旁组织中未有表达(P<0.05).免疫组化染色结果显示99例膀胱癌患者中有63例(63.64%)表达了CIP2A蛋白,而癌旁组织中未有表达(P<0.05).ELISA检测结果显示,CIP2A在膀胱癌患者外周血中的含量明显高于健康人群(中位数:0.015 2比0.001 8 ng/L,P<0.05).结论 CIP2A在膀胱癌患者的组织及血清中高表达,CIP2A可以作为反映膀胱癌生物学行为的有效指标. Objective To explore the expression of cancerous inhibitor of PP2A (CIP2A) and evaluate its role in bladder cancer.Methods RT-PCR was used to detect the expression of CIP2A mRNA from 38 cases of patients with bladder cancer and 12 cases of normal bladder tissue.The CIP2A protein expression levels in 99 cases of patients with bladder cancer and 12 cases of normal tissue was detected by immunohistochemical staining.And the serum contents of CIP2A protein of 38 patients with bladder cancer and 40 normal controls were detected by ELISA.Results The expression of CIP2A mRNA was detected in 29/38 cases (76.32%) of bladder cancer.And there was no expression in normal tissue (P <0.05).The positive rate of CIP2A protein was 63.64% in 99 cases of bladder cancer tissues and no expression detected in normal tissues(P < 0.05).ELISA results showed that the serum content of CIP2A in patients with bladder cancer was significantly higher than that in normal controls(median:0.015 2 vs 0.001 8 ng/L,P < 0.05).Conclusions The tissue and serum expressions of CIP2A in patients with bladder cancer are higher than those in normal controls.And CIP2A may be used as an indicator of the biological behavior of bladder cancer.
出处 《中华医学杂志》 CAS CSCD 北大核心 2014年第34期2681-2683,共3页 National Medical Journal of China
基金 国家临床重点专科建设项目(1311300002403) 山东省自然科学基金(ZR2011HL010)
关键词 膀胱肿瘤 肿瘤标记 生物学 CIP2A Urinary bladder neoplasms Tumor markers, biological Cancerous inhibitor of PP2A
  • 相关文献

参考文献8

  • 1邓建华,李汉忠,张玉石.非肌层浸润性膀胱癌进展风险研究现状[J].中华医学杂志,2014,94(22):1758-1759. 被引量:17
  • 2Junttila MR,Puustinen P,Niemel(a) M,et al.CIP2A inhibits PP2A in human malignancies[J].Cell,2007,130:51-62.
  • 3Li W,Ge Z,Liu C,et al.CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity,senescence,or differentiation of tumor cells[J].Clin Cancer Res,2008,14:3722-3728.
  • 4C(o)me C,Laine A,Chanrion M,et al.CIP2A is associated with human breast cancer aggressivity[J].Clin Cancer Res,2009,15:5092-5100.
  • 5夏冰,郭青,赵伟鹏,郭姗琦,田晨,张翼鷟.c—Myc在骨髓基质细胞介导的急性髓细胞白血病耐药中作用[J].中华医学杂志,2013,93(22):1746-1749. 被引量:3
  • 6Arroyo JD,Hahn WC.Involvement of PP2A in viral and cellular transformation[J].Oncogene,2005,24:7746-7755.
  • 7Khanna A,B(o)ckelman C,Hemmes A,et al.MYC-dependent regulation and prognostic role of CIP2A in gastric cancer[J].J Natl Cancer Inst,2009,101:793-805.
  • 8Braig M,Lee S,Loddenkemper C,et al.Oncogene-induced senescence as an initial barrier in lymphoma development[J].Nature,2005,436:660-665.

二级参考文献40

  • 1张薇,项永兵,刘振伟,方茹蓉,阮志贤,孙璐,高立峰,金凡,高玉堂.1973-1999年上海市区老年人恶性肿瘤发病趋势分析[J].中华老年医学杂志,2005,24(9):701-704. 被引量:85
  • 2周梁,史本涛,王盛兴,罗勇,杨林,张林琳,王新阳,贺大林.表浅性与浸润性膀胱癌基因表达谱的比较[J].中华医学杂志,2007,87(12):798-801. 被引量:4
  • 3Hoffman B, Amanullah M, Shafarenko M, et al. The proto- oncogene c-rnyc in hematopoietic development and leukemogenesis. Oncogene, 2002, 21: 3414-3421.
  • 4Luo H, Li Q, O'Neal J, et al. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma- associated antiapoptotic mutations. Blood, 2005, 106: 2452- 2461.
  • 5Tondreau T, MeuIeman N, Delforge A, eta]. Mesencbymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells, 2005,23 : 1105-1112.
  • 6Lwiu T, Lin J, Chni YS, et al. Follicular dendritic cell- dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-roediated Bim down-regulation through induction of microRNA-18la. Blood, 2010, 116: 5228-5236.
  • 7Lin J, Lwin T, Zhao JJ, et al. Follicular dendritic cell-induced microRNA- mediated upregulation of PRDMI and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia,2011 , 25 : 145-152.
  • 8Carrancio S, Blanco B, Romo C, et al. Bone mmTow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone mmTow microenvironment. PLoS One, 2011, 6:e26241.
  • 9Schraufstatter IU, Discipio RG, Khaldoyanidi S. Mesenchymal stem cells and their microenvironment. Front Bosci, 2011, 16: 2271-2288.
  • 10Vianello F, Villanova F, Tisato V, et al. Bone marrow mesenehymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-indueed apoptosis via the CXCR4/ CXCL12 axis. Haematologica, 2010,95 : 1081-1089.

共引文献18

同被引文献23

  • 1刘东亮,冉隆建,卢一平,石海燕,朱蜀侠,吕健为,胥艳,荣霞.钬激光照射抑制膀胱肿瘤细胞株T-24增殖活性和诱导其凋亡的研究[J].中华实验外科杂志,2007,24(8):951-953. 被引量:1
  • 2Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies[ J]. Cell,2007,130 : 51-62.
  • 3Xue Y,Wu G,Wang X,et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma[ J]. Med Oncol, 2013,30:406.
  • 4Huang LP, Savoly D, Sidi AA, et al. CIP2A protein expression in high-grade, high-stage bladder cancer[ J]. Cancer Med,2012,1 : 76 -81.
  • 5Khanna A, BSckelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer[ J]. J Natl Cancer Inst,2009,101:793-805.
  • 6Li W, Ge Z, Liu C,et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells [ J ]. Clin Cancer Res,2008,14:3722- 3728.
  • 7Wang J, Li W, Li L, et al. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 ceils proliferation and differentiation[ J]. Int J Lab Hematol.2011.33 :290-298.
  • 8Wai PY, Kuo PC. Osteopontin : regulation in tumor metastasis [ J ]. Cancer Metastasis Rev ,2008,27 : 103-118.
  • 9Park MG, Oh MM, Yoon JY, et al. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study [ J]. Kaohsiung J Med Sci,2012 ,28:525-530.
  • 10Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis [ J]. Curr Mol Med, 2006,8:819-830.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部